Microorganisms conduct fermentation and create secondary metabolites. Adjustments in growth environments can be used to make these organisms covert economical carbon sources (starch, sucrose, glucose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into highly useful key intermediates or microbial APIs (such as antibiotics vitamins, amino acids).
APIs are the biological/synthetic active constituent of a pharmaceuticals. Popular production techniques include chemical synthesis, fermentation, recombinant DNA, isolation, & natural source recovery. A drug's API is used to treat, detect, mitigate, as well as prevent diseases and is used in various pharmaceuticals for conditions such as oncology, CNS disorders, diabetes, neurological diseases, respiratory and cardiovascular disorders, and others.
The increasing prevalence of chronic illnesses such as Alzheimer's disease and others is expected to drive the demand for microbial API. According to the Alzheimer's Association, 6.5 million individuals in the U.S. were suffering from Alzheimer’s disease in 2022. It is the sixth leading cause of death in the U.S., and has a higher prevalence rate in people over 65. This figure is expected to increase to 13 million by 2050, increasing the demand for associated drugs and microbial API.
Increased demand for biological products, amino acids, and antibiotics is driving the growth of the global microbial API market. Furthermore, the growing need to fulfill nutritional requirements is anticipated to increase end-user adoption of microbially derived vitamins in the upcoming years. The market demand for microbial APIs is attributed to characteristics such as non-toxicity, ease of availability, and high specificity. Their major application areas include pharmaceutical and biotechnology industries, hospitals, and research facilities. In addition, increased immunization against infectious diseases and expanding applications in the pharmaceutical industry are further driving growth in the microbial API market.
Segments |
Details |
Type |
Antibiotics, Amino acids, Vitamins, Nucleotides, Organic Acids, Biological Products, Hormones |
Application |
Hospitals, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies. |
Region |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Major companies operating in the microbial API market include Merck & Co., Inc., HGPF, Huaxing, North China Pharmaceutical Co Ltd, Topfond Pharmaceutical Co., Ltd., DSM, Tianjin Tianyao Pharmaceuticals Co., Ltd., CSPC Pharma, KOLON LIFE SCIENCE, Northeast Pharm, Shandong Lukang Pharmaceutical Co., Ltd., Luwei Pharmaceutical Group Co., Ltd., Jiangshan (DSM). Companies are aiming at the expansion of manufacturing plants. However, the stringent FD regulations are hindering the overall market growth and capacity upgradation plants of players in the industry.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.